1 / 12

Adult Vaccine Market to reach US$ 22 Billion by 2024

Access full Research: https://www.renub.com/adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php As per Renub Research analysis Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024. Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable diseases. Several organizations such as Global Immunization Vision and Strategy (GIVS), WHO’s Global Vaccine Action Plan, The GAVI Alliance are putting their best to reduce the occurrence of vaccine-preventable diseases around the world which certainly is driving the adult vaccine market sturdily. Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period.

renubresearch
Download Presentation

Adult Vaccine Market to reach US$ 22 Billion by 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category: Vaccines Market Research Report

  2. Adult Vaccine Market Analyst View: • Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024. • GetFree Customization in this Report • Research Report Title: • Adult Vaccine Market, Global Analysis By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella and Travel & Miscellaneous Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others) • Access Full Research:  • https://www.renub.com/adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php

  3. Adult Vaccine Market is projected to reach US$ 22 Billion by 2024. As per Renub Research analysis Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024. Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable diseases. Several organizations such as Global Immunization Vision and Strategy (GIVS), WHO’s Global Vaccine Action Plan, The GAVI Alliance are putting their best to reduce the occurrence of vaccine-preventable diseases around the world which certainly is driving the adult vaccine market sturdily. Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period. Request a free sample copy of the report:  https://www.renub.com/contactus.php

  4. Adult Vaccine Market is projected to reach US$ 22 Billion by 2024. Renub Research report titled “Adult Vaccine Market, Global Analysis By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella and Travel & Miscellaneous Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Adults Vaccine Market. By Disease - Pneumococcal Vaccine is likely to grow at noteworthy rate over the coming years The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella, and Travel & Miscellaneous Vaccine. Pneumococcal and Hepatitis together hold the significant market share in global adult vaccine market and is expected to continue so in the forecast period. By End User – Global Adults Vaccine Market: The report studies the market by end user as Adults. Around the world, thousands of adults become seriously ill, get hospitalized and even die because of diseases that vaccines can help prevent. By getting vaccinated, one can help protect themselves from much of this needless suffering.

  5. Adult Vaccine Market is projected to reach US$ 22 Billion by 2024.

  6. Pediatric Vaccine Market is projected to exceed US$ 48 Billion by 2024. Almost 350 Million Adults get vaccinated by 2024 Due to the increasing prevalence of diseases and growing awareness regarding the vaccine-preventable diseases, it is estimated that by the year 2024, nearly 350 million adults get vaccinated; in order to protect themselves from diseases. Some of the vaccines which hold considerable share in terms of adult vaccination include Influenza, Hepatitis, HPV and Pneumonia vaccine. Company Analysis GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report. Regional - Immunization Profile The report also studies the Immunization profile around the world; By Disease - Measles, Mumps, Rubella, Japanese encephalitis, Tetanus, Pertussis, Yellow Fever. While By Regions, it studies Americas (AMR), Europe (EUR), Africa (AFR), Eastern Mediterranean (EMR), South-East Asia (SEAR), Western Pacific (WPR) and Global.

  7. Adult Vaccine Market is projected to reach US$ 22 Billion by 2024. Client can Purchase this Report in Sections from below link: Access full Research: https://www.renub.com/adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php Global Adults Vaccine Market has been extensively studied from 3 major points: 1.    Adult Vaccines (Disease wise) Market & Forecast2.    Number of Vaccinated Adults (Disease wise) & Forecast3.    Doses of Vaccines Administered in Adults(Disease wise) & Forecast  By Disease •    Influenza •    Cervical Cancer•    Zoster (Shingles) •    MMR •    Pneumonia •    Meningitis•    Hepatitis •    Tap (Diphtheria, Tetanus, Pertussis)•    Varicella •    Travel & Miscellaneous Vaccine

  8. Table of Contents for Adult Vaccine Market Key Companies Covered in the Report •    GlaxoSmithKline•    Merck•    Sanofi•    Pfizer Key Topics Covered 1.    Research Findings 2.    Adult Vaccines Market (2011 – 2024) 3.    Market & Numbers Share - Adult Vaccines 3.1    Adult Vaccine Market Share 3.2    Adult Vaccinated Population Share 3.3    Adult Doses of Vaccines Administered Share 3.4    Vaccine Companies Market Share 4.    Adult Vaccinated Numbers 5.    Adult Doses of Vaccines Administered

  9. Table of Contents for Adult Vaccine Market 6.    Disease wise – Adult Vaccines Market (2011 – 2024) 6.1    Influenza 6.2    Cervical Cancer (HPV) 6.3    Zoster (Shingles) 6.4    MMR 6.5    Pneumococcal 6.6    Meningococcal 6.7    Hepatitis 6.8    TdaP 6.9    Travel and Miscellaneous 6.10    Varicella 7.    Disease wise – Numbers of Vaccinated Adults (2011 – 2024) 7.1    Influenza 7.2    Cervical Cancer (HPV) 7.3    Zoster (Shingles) 7.4    MMR 7.5    Pneumococcal 7.6    Meningococcal 7.7    Hepatitis 7.8    TdaP 7.9    Varicella 8.    Disease wise – Doses of Vaccines Administered in Adults (2011 – 2024) 8.1    Influenza 8.2    Cervical Cancer (HPV) 8.3    Zoster (Shingles) 8.4    MMR 8.5    Pneumococcal 8.6    Meningococcal 8.7    Hepatitis 8.8    TdaP 8.9    Varicella

  10. Table of Contents for Adult Vaccine Market 9.    Disease wise - Immunization Profile 9.1    Immunization Coverage (%) in Infants 9.2    Global Immunization Profile 9.3    By Geographic Region – Immunization Profile 10.    Vaccines Key Players Sales (2011 – 2024) 10.1    GlaxoSmithKline, plc.’s Vaccines Sales 10.2    Merck & Co. Vaccines Sales 10.3    Sanofi Pasteur’s Vaccines Sales 10.4    Pfizer, Inc.’s Vaccines Sales 10.5    Global – Other Companies Vaccines Sales 11.    Vaccines – Products and Pipeline 11.1    GSK Vaccine Product Pipeline 11.2    Merck Vaccine Product Pipeline 11.3    Sanofi Vaccine Product Pipeline 11.4    Pfizer Vaccine Product Pipeline 12.    Top Mergers and Acquisitions in the Vaccine Industry 13.    Vaccines and Regulator’s Interventions 13.1    Making and Meeting Standards of Quality and Safety 13.2    Vaccine Funding

  11. Table of Contents for Adult Vaccine Market 14.    Vaccine Market Drivers 14.1    Inclusion in National Immunization Schedule 14.2    Growing Immunization Coverage for HPV Vaccines 14.3    Increase in Prevalence of Infectious Diseases 14.4    Global Immunization Vision and Strategy (GIVS) 14.5    GAVI Model Fuelling Vaccine Manufacturers 14.6    Increasing Vaccine Availability in United States 14.7    The Vaccine Safety Data link Project 14.8    The Vaccine Injury Compensation Program 14.9    Transforming of Vaccine Technologies 14.10    Global Vaccine Action Plan by WHO (2011 - 2020) 14.11    Continuous Focus on Effective Communication Strategies 15.    Vaccines Market Challenges 15.1    Hurdles to Optimal use of Licensed Vaccines 15.2    Complexity of Vaccine Development & Approval System Thwarts Product Development 15.3    Shortening the Timeline for Vaccine Development 15.4    Refusal/Resistance to Vaccination 15.5    Vaccine Shortages and Delays 15.6    Obstacles in Vaccine Research & Development 15.7    Barriers to New Entrants in the Vaccines Market

  12. GetFree Customization in this Report Vaccines Market Reports: https://www.renub.com/vaccines-12-c.php

More Related